{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:31:51Z","timestamp":1784079111391,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.eururo.2015.11.030","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T21:15:06Z","timestamp":1450473306000},"page":"1016-1025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol"],"prefix":"10.1016","volume":"69","author":[{"given":"Ruth E.","family":"Langley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard G.","family":"Kynaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla A.","family":"Alhasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinh","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar M.","family":"Paez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Jovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Scrase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay","family":"Cafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Welland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Honeyfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.11.030_bib0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2012.523","article-title":"Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"Bourke","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2015.11.030_bib0195","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1172\/JCI106185","article-title":"Conversion of blood androgens to estrogens in normal adult men and women","volume":"48","author":"Longcope","year":"1969","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2015.11.030_bib0200","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.11.030_bib0205","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","article-title":"Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression","volume":"175","author":"Morote","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0210","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.11.030_bib0215","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0220","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0225","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.11.030_bib0235","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","article-title":"Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications","volume":"111","author":"Shao","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.11.030_bib0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/21681805.2013.861508","article-title":"Diethylstilboestrol for the treatment of prostate cancer: past, present and future","volume":"48","author":"Turo","year":"2014","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0245","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C","article-title":"Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate","volume":"32","author":"Byar","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.11.030_bib0250","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/pros.2990140410","article-title":"Estrogen therapy and liver function--metabolic effects of oral and parenteral administration","volume":"14","author":"von Schoultz","year":"1989","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.11.030_bib0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1464-410X.1990.tb14728.x","article-title":"Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma","volume":"65","author":"Henriksson","year":"1990","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0260","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0265","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1464-410X.2008.07583.x","article-title":"Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer","volume":"102","author":"Langley","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.11.030_bib0270","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.11.030_bib0275","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1081\/ERC-120022298","article-title":"Lumbar bone mineral density in prostate cancer patients with bone metastases","volume":"29","author":"Chang","year":"2003","journal-title":"Endocr Res"},{"key":"10.1016\/j.eururo.2015.11.030_bib0285","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/humupd\/6.5.419","article-title":"Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995","volume":"6","author":"Doren","year":"2000","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.eururo.2015.11.030_bib0290","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1097\/01.ju.0000145511.56476.00","article-title":"Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer","volume":"172","author":"Ockrim","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0295","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/00365590801943274","article-title":"Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5","volume":"42","author":"Hedlund","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0300","first-page":"3","article-title":"Uses and limitations of bone mineral density measurements in the management of osteoporosis","volume":"7","author":"Small","year":"2005","journal-title":"MedGenMed"},{"key":"10.1016\/j.eururo.2015.11.030_bib0305","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.11.030_bib0310","first-page":"42","article-title":"Androgen deprivation therapy and the re-emergence of parenteral oestrogen in prostate cancer","volume":"10","author":"Phillips","year":"2014","journal-title":"Oncol Haematol Rev"},{"key":"10.1016\/j.eururo.2015.11.030_bib0315","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2015.11.030_bib0320","first-page":"143","article-title":"Oestrogen action on bone cells","volume":"2","author":"Krassas","year":"2001","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.eururo.2015.11.030_bib0325","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.3747\/co.v18i4.746","article-title":"A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy","volume":"18","author":"Lee","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0330","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Serpa Neto","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2015.11.030_bib0335","doi-asserted-by":"crossref","first-page":"h4580","DOI":"10.1136\/bmj.h4580","article-title":"Calcium intake and risk of fracture: systematic review","volume":"351","author":"Bolland","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2015.11.030_bib0340","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(13)61647-5","article-title":"Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis","volume":"383","author":"Reid","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.11.030_bib0345","doi-asserted-by":"crossref","first-page":"h4183","DOI":"10.1136\/bmj.h4183","article-title":"Calcium intake and bone mineral density: systematic review and meta-analysis","volume":"351","author":"Tai","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2015.11.030_bib0350","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.11.030_bib0355","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.11.030_bib0360","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.11.030_bib0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.11.030_bib0370","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0090-4295(99)00580-4","article-title":"Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 trial study","volume":"55","author":"Hedlund","year":"2000","journal-title":"Urology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815012014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815012014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T14:45:57Z","timestamp":1567435557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815012014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0302283815012014"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.11.030","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}